Pfizer said on Tuesday the next few years will be bumpy, beginning with 2026, due to lower sales of its COVID vaccine and ...

Pfizer's profits will fall short of Wall Street estimates next year, as it faces weaker sales of COVID products and squeezed ...

Pfizer (PFE) stock falls, and its COVID vaccine peers such as Moderna (MRNA) and Novavax (NVAX) also drop as the company ...

Alongside its cost-cutting strategy, Pfizer has been investing into its cardiometabolic pipeline in a bid to enter the ...

Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...

Commissioner Marty Makary on Monday denied recent reports suggesting plans for his agency to add a black box warning onto ...

The COVID-19 vaccines developed for the 2024-2025 respiratory disease season were around 75% effective at preventing ...

Now in 2025, the TGA has registered Pfizer's LP.8.1 vaccine, designed specifically to target the spike protein of LP.8.1.

Built into the 2026 guidance is a $1.5 billion decline in sales of its COVID products—from an estimated $6.5 billion this ...

Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit ...

In a surprising turn of events, Pfizer has adjusted its profit forecast for 2026, indicating a potential decline in earnings that falls short of Wall Street expectations. This announcement has raised ...